AIM ImmunoTech Inc. 8-K

What Happened AIM ImmunoTech Inc. (AIM) filed a Form 8-K on May 14, 2026 furnishing a press release and a Virtual Investor Key Opinion Leader Connect Segment video. The Segment features Professor Casper H.J. van Eijck, MD, PhD (Professor and Pancreato-biliary Surgeon at Erasmus Medical Center and a consultant to AIM) and Thomas K. Equels, MS, JD, AIM’s Chief Executive Officer. The video was posted on the Virtual Investor site at https://virtualinvestorco.com/aim/. The company notes the information is “furnished” (Exhibit 99.1) and is not “filed” for purposes of Section 18 of the Securities Exchange Act.

Key Details

• Press release and Segment date: May 14, 2026.
• Participants: Prof. Casper H.J. van Eijck (consultant, Erasmus Medical Center) and CEO Thomas K. Equels.
• Video location: https://virtualinvestorco.com/aim/ (posted by Virtual Investor).
• Regulatory note: Information is furnished, not filed; Exhibit 99.1 accompanies the 8-K.

Why It Matters This 8-K communicates that AIM is sharing a recorded investor-focused presentation featuring a clinical expert and the CEO, which may provide investors with management commentary and expert perspective on the company’s programs. Because the material is furnished (not filed), it is not subject to the liability protections of Section 18; investors should review the press release and video directly on the posted site for any substantive updates.